Publication | Closed Access

Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta

MechanobiologySclerostinDevelopmental BiologyImmunologyBone RepairOsteoarthritisCombination Sclerostin AntibodyOsteogenesisBone RemodelingOsteoporosisSclerodermaMedicineMouse ModelOrthopaedic SurgeryOsteogenesis ImperfectaOsteocalcin